These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 15319035)

  • 1. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector.
    Liu YL; Mingozzi F; Rodriguéz-Colôn SM; Joseph S; Dobrzynski E; Suzuki T; High KA; Herzog RW
    Hum Gene Ther; 2004 Aug; 15(8):783-92. PubMed ID: 15319035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
    Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
    Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
    Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW
    Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functions of AAV-CMV-F.IX And AAV-EF1alpha-F.IX in gene therapy for hemophilia B.
    Wiwanitkit V
    Hum Gene Ther; 2007 Feb; 18(2):89-92. PubMed ID: 17266422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle as a target for supplementary factor IX gene transfer.
    Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW
    Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
    Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
    Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA
    Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
    Hasbrouck NC; High KA
    Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
    Arruda VR; Schuettrumpf J; Herzog RW; Nichols TC; Robinson N; Lotfi Y; Mingozzi F; Xiao W; Couto LB; High KA
    Blood; 2004 Jan; 103(1):85-92. PubMed ID: 12969984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
    Manno CS; Chew AJ; Hutchison S; Larson PJ; Herzog RW; Arruda VR; Tai SJ; Ragni MV; Thompson A; Ozelo M; Couto LB; Leonard DG; Johnson FA; McClelland A; Scallan C; Skarsgard E; Flake AW; Kay MA; High KA; Glader B
    Blood; 2003 Apr; 101(8):2963-72. PubMed ID: 12515715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
    Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
    Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter.
    Hagstrom JN; Couto LB; Scallan C; Burton M; McCleland ML; Fields PA; Arruda VR; Herzog RW; High KA
    Blood; 2000 Apr; 95(8):2536-42. PubMed ID: 10753832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.
    Buchlis G; Podsakoff GM; Radu A; Hawk SM; Flake AW; Mingozzi F; High KA
    Blood; 2012 Mar; 119(13):3038-41. PubMed ID: 22271447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector.
    Mingozzi F; Schüttrumpf J; Arruda VR; Liu Y; Liu YL; High KA; Xiao W; Herzog RW
    J Virol; 2002 Oct; 76(20):10497-502. PubMed ID: 12239326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice.
    Sabatino DE; Mackenzie TC; Peranteau W; Edmonson S; Campagnoli C; Liu YL; Flake AW; High KA
    Mol Ther; 2007 Sep; 15(9):1677-85. PubMed ID: 17565352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAV-mediated gene transfer for hemophilia.
    High KA
    Ann N Y Acad Sci; 2001 Dec; 953():64-74. PubMed ID: 11795424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice.
    Xu L; Daly T; Gao C; Flotte TR; Song S; Byrne BJ; Sands MS; Parker Ponder K
    Hum Gene Ther; 2001 Mar; 12(5):563-73. PubMed ID: 11268288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.